Adherence to interferon β treatment in Kosovan multiple sclerosis registry

Published: 9 January 2024
Abstract Views: 637
PDF: 146
HTML: 59
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Background. Because of side effects, adherence to the treatment with β interferons in multiple sclerosis (MS) is low, leading to decreased treatment efficacy. This can be challenging, especially in healthcare systems where these medications are the only therapeutic option for the treatment of MS. The number of missed doses was calculated as a difference between the number of doses a patient had to withdraw from the treatment start to the cut-off date and the real number of doses taken from the MS unit. Missed doses were compared to gender, age, time since the diagnosis, time from the diagnosis to the treatment start, clinical type of MS, expanded disability status scale (EDSS), and duration of the treatment. Results showed that the adherence rate during the follow-up period was 73.8%. Patients above 40 years of age (P<0.005), higher EDSS (P<0.001), longer duration of the disease (P<0.001), longer waiting time from the diagnosis to the treatment initiation (P<0.001), and longer time on interferons (P<0.001) had lower adherence rates to the treatment. In conclusion, the findings were in correlation with studies that have used similar criteria for the determination of adherence and supported reports that adherence rate decreases with time and poses a challenge to the overall efficacy of the treatment.



PlumX Metrics


Download data is not yet available.


Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005;252:iii3-9. DOI:
Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622. DOI:
Compston A, Coles A. Multiple Sclerosis. Lancet 2008;372:1502-17. DOI:
Brown MT, Bussell JK. Medication adherence: WHO cares?. InMayo clinic proceedings. Elsevier 2011;86:304-14. DOI:
Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7. DOI:
Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19:24-40. DOI:
O’Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50. DOI:
Portaccio E, Zipoli V, Siracusa G, et al. Long term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59:131-5.
Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9. DOI:
Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease modifying therapy in MS. J Neurol 2009;256:568-76. DOI:
Tremlett HL, Oger J. Interrupted therapy: stopping and switching for the B-interferons prescribed for MS. Neurology 2003;61:551-4. DOI:
McKay KA, Tremlett H, Patten SB, et al. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study. Mult Scler J 2017;23:588-96. DOI:
Köşkderelioğlu A, Gedizlioğlu M, Ortan P, Özge ÖC. Evaluation of the adherence to immunmodulatory treatment in patients with multiple sclerosis. Nöro Psikiyatri Arşivi 2015;52:376. DOI:
Costello K, Kennedy P, Scanzillo JO. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008;10:225.
Halpern R, Agarwal S, Dembek C, et al. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 2011;5:73-84. DOI:
Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94. DOI:
Katrych O, Simone T, Azad S, Mousa S. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. CNS &Amp; Neurological Disorders - Drug Targets 2009;8:512-9. DOI:
Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100. DOI:
Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77. DOI:
Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon β therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008;59:131-5. DOI:
Cunningham A, Gottberg K, Von Koch L, Hillert J. Nonadherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Acta neurologica scandinavica 2010;121:154-60. DOI:
Correia I, Marques IB, Sousa M, et al. Predictors of firstline treatment persistence in a Portuguese cohort of relapsing- remitting multiple sclerosis. J Clin Neurosci 2016;36:73-8. DOI:
Lopez-Mendez P, Rio J, Perez-Ricart A, et al. Therapy adherence to immunomodulator treatment in patients with multiple sclerosis. Rev Neurol 2013;56:8-12.
Bartolomé-García E, Usarralde-Pérez Á, Sanmartín-Fenollera P, Pérez-Encinas M. Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis. Eur J Hosp Pharma 2019;26:23-8. DOI:
Ślusarz R, Olkiewicz J, Bonek R, et al. The impact of motor disability and the level of fatigue on adherence to therapeutic recommendations in patients with multiple sclerosis treated with immunomodulation. Int J Med Sci 2021;18:3609-14. DOI:
Raffel J, Gafson A, Dahdaleh S, et al. Inflammatory activity on natalizumab predicts short-term but not longterm disability in multiple sclerosis. Plos One 2017;12:e0169546. DOI:
Kingwell E, Leray E, Zhu F, et al. Multiple sclerosis: effect of beta interferon treatment on survival. Brain 2019;142:1324-33. DOI:
Kaufmann M, Kuhle J, Puhan MA, et al. Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland. Mult Scler J Exp Transl Clin 2018;4:2055217318814562. DOI:

How to Cite

Myftiu, B., Komoni, E., Malazogu, E., Jashari, F., Beqiri Rashiti, S., Pushka, M., Biqku, A., Aliçkaj Prebreza, S., Rrahmani Spanca, V., Rrustemi Bytyqi, J., Shala, N., & Blyta, A. (2024). Adherence to interferon β treatment in Kosovan multiple sclerosis registry. Italian Journal of Medicine, 18(1).